Bcal Diagnostics Ltd Asset Resilience Ratio
Bcal Diagnostics Ltd asset resilience ratio. Bcal Diagnostics Ltd (BDX) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Bcal Diagnostics Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bcal Diagnostics Ltd (2021–2022)
Asset resilience ratio of Bcal Diagnostics Ltd from 2021 to 2022. This chart shows how Bcal Diagnostics Ltd's Asset Resilience Ratio has changed over time. Read BDX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bcal Diagnostics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Bcal Diagnostics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bcal Diagnostics Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bcal Diagnostics Ltd Industry Peers by Asset Resilience Ratio
Compare Bcal Diagnostics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Bcal Diagnostics Ltd Asset Resilience Ratio by Year (2021–2022)
Bcal Diagnostics Ltd asset resilience ratio by year from 2021 to 2022. The table below shows the annual Asset Resilience Ratio data for Bcal Diagnostics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$8.37 Million ≈ $5.92 Million |
-- |
| 2021-12-31 | 37.77% | AU$4.00 Million ≈ $2.83 Million |
AU$10.59 Million ≈ $7.49 Million |
-- |
About Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 an… Read more